Pharmacologic treatment strategies and association with major neonatal outcomes for patent ductus arteriosus in preterm infants

Category	Detail
Condition	Patent Ductus Arteriosus (PDA)
Key Mechanisms	Pharmacologic treatment promotes ductal closure but its impact on outcomes is uncertain.
Target Population	Preterm infants born at <32 weeks’ gestation.
Care Setting	Tertiary-level neonatal intensive care unit.

Study included 76 preterm infants with a median gestational age of 28 weeks.
Composite outcome of bronchopulmonary dysplasia (BPD) and/or mortality occurred in 51.3% of infants.
Gestational age was the strongest independent predictor of BPD and/or mortality.
Treatment category (ibuprofen, paracetamol, or sequential therapy) was not independently associated with outcomes.
Pharmacologic treatment strategies did not show significant differences in major neonatal outcomes.

Echocardiographic assessment is recommended for PDA diagnosis in preterm infants.

Pharmacologic treatment options include ibuprofen and paracetamol, influenced by clinical factors.

Consider risks associated with pharmacologic treatment, including renal function and bleeding risk.

Preterm infants with clinically significant PDA.

Treatment strategies evaluated include ibuprofen only, paracetamol only, and sequential therapy.

Conduct routine echocardiographic screening within the first 5 postnatal days for eligible infants.
Utilize a multidisciplinary assessment for treatment decisions regarding PDA.

Clinical Scorecard: Pharmacological Approaches and Their Relationship with Key Neonatal Outcomes in Preterm Infants with Patent Ductus Arteriosus